Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pyrotinib Plus Trastuzumab|DRUG: Pertuzumab Plus Trastuzumab
Sponsor: Fudan University